Bellevue Group’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.78M | Buy |
326,751
+95,754
| +41% | +$1.11M | 0.08% | 86 |
|
|
2025
Q1 | $2.02M | Sell |
230,997
-39,731
| -15% | -$347K | 0.05% | 101 |
|
|
2024
Q4 | $3.89M | Sell |
270,728
-11,153
| -4% | -$160K | 0.07% | 99 |
|
|
2024
Q3 | $6.36M | Sell |
281,881
-26,430
| -9% | -$597K | 0.1% | 95 |
|
|
2024
Q2 | $6M | Hold |
308,311
| – | – | 0.1% | 95 |
|
|
2024
Q1 | $11.6M | Buy |
308,311
+15,138
| +5% | +$568K | 0.18% | 89 |
|
|
2023
Q4 | $16.4M | Sell |
293,173
-1,259
| -0.4% | -$70.5K | 0.25% | 81 |
|
|
2023
Q3 | $12.1M | Sell |
294,432
-30,314
| -9% | -$1.25M | 0.2% | 85 |
|
|
2023
Q2 | $18.1M | Hold |
324,746
| – | – | 0.26% | 82 |
|
|
2023
Q1 | $18.1M | Hold |
324,746
| – | – | 0.26% | 83 |
|
|
2022
Q4 | $11.8M | Buy |
324,746
+70,612
| +28% | +$2.57M | 0.16% | 94 |
|
|
2022
Q3 | $7.24M | Sell |
254,134
-5,237
| -2% | -$149K | 0.1% | 104 |
|
|
2022
Q2 | $11.7M | Buy |
259,371
+6,512
| +3% | +$295K | 0.17% | 101 |
|
|
2022
Q1 | $19.2M | Buy |
252,859
+20,187
| +9% | +$1.54M | 0.22% | 94 |
|
|
2021
Q4 | $34.7M | Hold |
232,672
| – | – | 0.36% | 80 |
|
|
2021
Q3 | $33.9M | Hold |
232,672
| – | – | 0.34% | 87 |
|
|
2021
Q2 | $45.6M | Buy |
232,672
+3,633
| +2% | +$711K | 0.44% | 70 |
|
|
2021
Q1 | $41.5M | Buy |
229,039
+63,916
| +39% | +$11.6M | 0.44% | 74 |
|
|
2020
Q4 | $23.4M | Buy |
165,123
+11,134
| +7% | +$1.58M | 0.27% | 94 |
|
|
2020
Q3 | $19.2M | Buy |
153,989
+30,912
| +25% | +$3.85M | 0.27% | 90 |
|
|
2020
Q2 | $11M | Buy |
123,077
+29,230
| +31% | +$2.61M | 0.16% | 100 |
|
|
2020
Q1 | $5.85M | Sell |
93,847
-35,280
| -27% | -$2.2M | 0.11% | 111 |
|
|
2019
Q4 | $9.85M | Buy |
129,127
+29,127
| +29% | +$2.22M | 0.16% | 90 |
|
|
2019
Q3 | $5.04M | Buy |
+100,000
| New | +$5.04M | 0.09% | 110 |
|